# FORM 4 Check this box if no longer subject to Section 16. Form

(Print or Type Responses)

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL					
OMB Number:	3235-0287				
Estimated average burden hours per					
resnonse	0.5				

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person   Hertzberg Richard				Issuer Name and Ticker or Trading Symbol Cellectar Biosciences, Inc. [clrB]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner						
1329 STRATFOR	(First) (Middle) 3. Date of Earliest Transaction 08/09/2016						saction (Month	onth/Day/Year)				Officer (give title below) X Other (specify below)  significant owner					
(Street) DEL MAR, CA 92014				4. If Amendment, Date Original Filed(Month/Day/Year)							6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person _Form filed by More than One Reporting Person						
(Chr) (Chr)						ies Acqui	nired, Disposed of, or Beneficially Owned										
1.Title of Security (Instr. 3)		2. Transactio Date (Month/Day/	Year) Execution		Date, if	(Instr. 8)	or Disposed of (D) (Instr. 3, 4 and 5)		5. Amount of Securitie Following Reported To (Instr. 3 and 4)					Beneficial			
				(Month/I		ay/ rear	Code	V A	moun	(A) or (D)	Price				Direct (D) Ownersh: or Indirect (Instr. 4) (I) (Instr. 4)		
Cellectar Bioscier	nces, Inc. cor	nmon stock (CLR	B) 10/31/2016	10/3	31/20	16	S	V 2	1,000	D	\$ 2.029	280,000				D	
Reminder: Report on	a separate line	e for each class of sec	curities beneficially	owned dir	ectly o	or indire											
							a		quir	ed to resp					ed in this forn ly valid OMB	n SEC	1474 (9-02)
			Tab				ities Acquired					ed					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date Secution Date, (Month/Day/Year) Any (Month/Day/Year)		(Instr. 8) Sec (A) (D)		Derivat Securit (A) or I (D)	tive	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	Securities Beneficially Owned Following	Ownership Form of Derivative Security: Direct (D)	Beneficial	
				Code	V	(A)		Date Exercisal		Expiration Date	Title		Amount or Number of Shares		Reported Transaction(s) (Instr. 4)	or Indirect (I) (Instr. 4)	
Cellectar Biosciences Inc. Warrant	\$ 46.80	08/09/2016		S	V		40,916	08/21/20	014 0	08/20/2019	Bioscie	ellectar ences, Inc. non stock	40,916	\$ 1.75	0	D	

### **Reporting Owners**

D # 0 Y // II	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
Hertzberg Richard 1329 STRATFORD COURT DEL MAR, CA 92014				significant owner			

## **Signatures**

Richard Hertzberg	11/01/2016
Signature of Reporting	Date

### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) CLRB stock sales during period October 13 through October 31, 2016
- (2) Price of CLRB at close of market 11/1/2016

#### Remarks:

Total CLRB beneficial ownership percentage of Hertzberg at 10/31/2016 based upon 5,368,235 total outstanding shares of CLRB reported by company as of 10/31/2016 is five and two/tenths percent

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.